These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 21323546)
21. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Lalwani GA; Berrocal AM; Murray TG; Buch M; Cardone S; Hess D; Johnson RA; Puliafito CA Retina; 2008 Mar; 28(3 Suppl):S13-8. PubMed ID: 18317338 [TBL] [Abstract][Full Text] [Related]
23. Dramatic regression of persistent tunica vasculosa lentis associated with retinopathy of prematurity following treatment with intravitreal bevacizumab. Goldman DR; Baumal CR J Pediatr Ophthalmol Strabismus; 2013 Jun; 50 Online():e27-9. PubMed ID: 24601434 [TBL] [Abstract][Full Text] [Related]
24. [Alarming use of anti-VEGF therapy in premature infants]. Hård AL; Hellström A Lakartidningen; 2011 Dec 7-13; 108(49):2600. PubMed ID: 22468401 [No Abstract] [Full Text] [Related]
25. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity. Kychenthal A; Dorta P Retina; 2010 Apr; 30(4 Suppl):S32-6. PubMed ID: 20224474 [TBL] [Abstract][Full Text] [Related]
26. Dramatic regression of persistent tunica vasculosa lentis associated with retinopathy of prematurity following treatment with intravitreal bevacizumab. Goldman DR; Baumal CR J Pediatr Ophthalmol Strabismus; 2013 Jun; 50 Online():e27-9. PubMed ID: 23739589 [TBL] [Abstract][Full Text] [Related]
27. Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab. Ittiara S; Blair MP; Shapiro MJ; Lichtenstein SJ J AAPOS; 2013 Jun; 17(3):323-5. PubMed ID: 23607977 [TBL] [Abstract][Full Text] [Related]
28. Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity. Harder BC; von Baltz S; Schlichtenbrede FC; Jonas JB Arch Ophthalmol; 2012 Jun; 130(6):800-1. PubMed ID: 22801850 [No Abstract] [Full Text] [Related]
29. Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (AP-ROP). Wutthiworawong B; Thitiratsanont U; Saovaprut C; Subhangkasen I; Geyuraphun B; Ampornprut A; Phumongkutchai J; Tephusdinnaayuthaya S J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S15-21. PubMed ID: 22043749 [TBL] [Abstract][Full Text] [Related]
30. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab. Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279 [TBL] [Abstract][Full Text] [Related]
31. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan. Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589 [TBL] [Abstract][Full Text] [Related]
32. Avastin as monotherapy for retinopathy of prematurity. Mintz-Hittner HA J AAPOS; 2010 Feb; 14(1):2-3. PubMed ID: 20227612 [No Abstract] [Full Text] [Related]
33. Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story. Quiroz-Mercado H; Ustariz-González O; Martinez-Castellanos MA; Covarrubias P; Dominguez F; Sanchez-Huerta V Semin Ophthalmol; 2007; 22(2):109-25. PubMed ID: 17564934 [TBL] [Abstract][Full Text] [Related]
34. Bevacizumab (avastin) for the treatment of retinopathy of prematurity. Beaulieu MJ Neonatal Netw; 2012; 31(4):242-7. PubMed ID: 22763251 [No Abstract] [Full Text] [Related]
36. What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity? Spandau U Acta Ophthalmol; 2013 Mar; 91(2):e154. PubMed ID: 22989079 [No Abstract] [Full Text] [Related]
37. Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies. Park SW; Jung HH; Heo H Acta Ophthalmol; 2014 Dec; 92(8):810-3. PubMed ID: 24909062 [No Abstract] [Full Text] [Related]
38. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Kong L; Mintz-Hittner HA; Penland RL; Kretzer FL; Chévez-Barrios P Arch Ophthalmol; 2008 Aug; 126(8):1161-3. PubMed ID: 18695118 [No Abstract] [Full Text] [Related]
39. Retinopathy of Prematurity: Intravitreal injections of bevacizumab: timing, technique, and outcomes. Mintz-Hittner HA J AAPOS; 2016 Dec; 20(6):478-480. PubMed ID: 27816750 [No Abstract] [Full Text] [Related]
40. Intravitreal bevacizumab for retinopathy of prematurity as first line or rescue therapy with focal laser treatment. A case series. Dani C; Frosini S; Fortunato P; Bertini G; Pratesi S; Pollazzi L; Caputo R; La Torre A J Matern Fetal Neonatal Med; 2012 Nov; 25(11):2194-7. PubMed ID: 22506618 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]